Crossmark

Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab

Crossref DOI link: https://doi.org/10.1186/s12885-023-11302-6

Published Online: 2023-08-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Okuno, Masayuki

Ishii, Takamichi

Ichida, Akihiko

Soyama, Akihiko

Takemura, Nobuyuki

Hirono, Seiko

Eguchi, Susumu

Hasegawa, Kiyoshi

Sasaki, Yasuharu

Uemura, Kohei

Kokudo, Norihiro

Hatano, Etsuro
License Information

Text and Data Mining valid from 2023-08-21

Version of Record valid from 2023-08-21
More Information

Article History

Received: 13 November 2022

Accepted: 14 August 2023

First Online: 21 August 2023

Declarations

:

: The authors declare no competing interests.

: This study was approved by the Kyoto University Certified institutional Review Board (CRB5180002). Permission to conduct this study was obtained from the administrators of all participating facilities. This study will be performed in accordance with the Declaration of Helsinki. Participants will provide written informed consent prior to participation in this study.

: Not applicable.

Document is current

Any future updates will be listed below